ILB’s mechanism of action may either reduce the triggers that lead to cell death or prevent further pathology even if triggers are present. By addressing the underlying processes of disease, ILB could significantly improve outcomes for people suffering from otherwise untreatable progressive and disabling conditions.

• Broad applicability in acute and neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and stroke plus traumatic brain injury and glaucoma.
• Addresses the underlying pathology of the diseases, enabling self-repair instead of just treating the symptoms.
• Subcutaneous dosing simplifies administration for the patient and makes it suitable for longer term treatment.